Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions Academic Article uri icon

Overview

MeSH Major

  • Cervical Intraepithelial Neoplasia
  • Cytodiagnosis
  • Papillomavirus Infections
  • Uterine Cervical Neoplasms
  • Vaginal Neoplasms

abstract

  • In clinical practice, the hrHPV test alone is not significantly superior to the Pap test as a primary screening method for cervicovaginal lesions. The false-negative rate of the hrHPV test in detecting biopsy-confirmed high-grade cervicovaginal lesions is comparable to the rate of the Pap test. Women with cytology and hrHPV cotesting, however, have a significantly lower false-negative rate than those undergoing either test alone. Currently, cytology-HPV cotesting remains the best strategy for detecting high-grade cervicovaginal lesions. Cancer Cytopathol 2016;124:317-23. © 2016 American Cancer Society.

publication date

  • May 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncy.21687

PubMed ID

  • 26774025

Additional Document Info

start page

  • 317

end page

  • 23

volume

  • 124

number

  • 5